Hamostaseologie 2018; 38(04): 240-246
DOI: 10.1055/s-0038-1673412
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Anticoagulation in Atherosclerotic Disease

Samer Al Said
1   Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
,
Christoph Bode
1   Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
,
Daniel Duerschmied
1   Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
› Author Affiliations
Further Information

Publication History

28 April 2018

13 August 2018

Publication Date:
17 October 2018 (online)

Abstract

The prevention of atherothrombotic events is an essential therapeutic goal in the treatment of patients with arteriosclerotic diseases. After plaque rupture, a rapidly growing thrombus can lead to acute vascular occlusion and thus heart attack, stroke or limb ischaemia. The acute therapy combines anticoagulation and platelet inhibition. However, the only available therapy so far in the primary and secondary prevention of stable patients is the platelet inhibitors aspirin and clopidogrel. Despite the use of antiplatelet therapies, including aspirin and P2Y12-receptor antagonists, some patients with artery disease continue to experience recurrent cardiovascular ischaemic events due to excessive thrombin generation beyond the acute period. As a result, studies have tested non-vitamin K antagonist oral anticoagulants (NOACs), specifically the factor Xa inhibitors, either alone or in combination with antiplatelet therapy, in the management of arterial disease. For the first time, the COMPASS study investigated low-dose anticoagulation in stable coronary heart disease or peripheral arterial disease. The addition of 2 × 2.5 mg rivaroxaban to long-term aspirin therapy not only prevented cardiovascular death, myocardial infarction and stroke, but even reduced all-cause mortality by a relative 18% after a mean follow-up of 23 months. This benefit came at the expense of more gastrointestinal bleeding, which might be reduced by the addition of a proton pump inhibitor (investigations are ongoing). Interestingly, however, there was no increase in fatal or intracranial haemorrhages. Therefore, a new standard therapy for high-risk patients with atherosclerotic disease may become available in the near future.

Zusammenfassung

Die Verhinderung atherothrombotischer Ereignisse ist ein wesentliches therapeutisches Ziel bei der Behandlung von Patienten mit arteriosklerotischen Erkrankungen. Ein schnell wachsender Thrombus kann nach Plaqueruptur zu akutem Gefäßverschluss und damit zu Herzinfarkt, Schlaganfall oder Ischämie der Extremitäten führen. Die Akuttherapie kombiniert Antikoagulation und Thrombozytenhemmung. Die bislang einzige verfügbare Therapie in der Primär- und Sekundärprävention stabiler Patienten sind jedoch die Thrombozytenaggregationshemmer Aspirin und Clopidogrel. Trotz der Verwendung von Thrombozytenaggregationshemmern, einschließlich Aspirin und P2Y12-Rezeptorantagonisten, leiden einige Patienten mit Arterienerkrankungen weiterhin unter kardiovaskulären ischämischen Ereignissen, die auf eine übermäßige Thrombinbildung nach der akuten Phase zurückzuführen sind. Als ein Ergebnis haben Studien Nicht-Vitamin-K-Antagonist-orale Antikoagulantien (NOAKs) getestet, insbesondere die Faktor-Xa-Inhibitoren, entweder allein oder in Kombination mit einer Antiplättchen-Therapie bei der Behandlung von arteriellen Erkrankungen. Die COMPASS-Studie untersuchte erstmals die niedrig dosierte Antikoagulation bei stabiler koronarer Herzkrankheit oder peripherer arterieller Verschlusskrankheit. Die Zugabe von 2 × 2,5 mg Rivaroxaban zur Langzeit-Aspirintherapie verhinderte nicht nur kardiovaskulären Tod, Myokardinfarkt und Schlaganfall, sondern reduzierte sogar die Gesamtmortalität um 18% nach einer mittleren Nachbeobachtungszeit von 23 Monaten. Dieser Vorteil ging auf Kosten von mehr gastrointestinalen Blutungen, die durch die Zugabe eines Protonenpumpenhemmers reduziert werden könnten (Untersuchungen laufen noch). Interessanterweise gab es jedoch keine Zunahme von tödlichen oder intrakraniellen Blutungen. Daher könnte in naher Zukunft eine neue Standardtherapie für Hochrisikopatienten mit atherosklerotischer Erkrankung verfügbar werden.

 
  • References

  • 1 Welsh RC, Roe MT, Steg PG. , et al. A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. Am Heart J 2016; 181: 92-100
  • 2 Riegger J, Byrne RA, Joner M. , et al; Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort (PRESTIGE) Investigators. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. Eur Heart J 2016; 37 (19) 1538-1549
  • 3 Merlini PA, Bauer KA, Oltrona L. , et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90 (01) 61-68
  • 4 Eikelboom JW, Connolly SJ, Bosch J. , et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377 (14) 1319-1330
  • 5 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348 (9038): 1329-1339
  • 6 Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. ; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (07) 494-502
  • 7 Bhatt DL, Fox KA, Hacke W. , et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354 (16) 1706-1717
  • 8 Bhatt DL, Flather MD, Hacke W. , et al; CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49 (19) 1982-1988
  • 9 Wiviott SD, Braunwald E, McCabe CH. , et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
  • 10 Bhatt DL. Intensifying platelet inhibition--navigating between Scylla and Charybdis. N Engl J Med 2007; 357 (20) 2078-2081
  • 11 Wallentin L, Becker RC, Budaj A. , et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
  • 12 Bonaca MP, Bhatt DL, Cohen M. , et al; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372 (19) 1791-1800
  • 13 van Es RF, Jonker JJC, Verheugt FWA, Deckers JW, Grobbee DE. ; Antithrombotics in the Secondary Preventionof Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002; 360 (9327): 109-113
  • 14 Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347 (13) 969-974
  • 15 Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005; 143 (04) 241-250
  • 16 Andreotti F, Testa L, Biondi-Zoccai GGL, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006; 27 (05) 519-526
  • 17 Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 2003; 41 (4, Suppl S): 62S-69S
  • 18 Anand S, Yusuf S, Xie C. , et al; Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357 (03) 217-227
  • 19 Dewilde WJM, Oirbans T, Verheugt FW. , et al; WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381 (9872): 1107-1115
  • 20 Wallentin L, Wilcox RG, Weaver WD. , et al; ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003; 362 (9386): 789-797
  • 21 Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol 2010; (196) 407-418
  • 22 Oldgren J, Budaj A, Granger CB. , et al; RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32 (22) 2781-2789
  • 23 Alexander JH, Lopes RD, James S. , et al; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365 (08) 699-708
  • 24 Mega JL, Braunwald E, Wiviott SD. , et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (01) 9-19
  • 25 Mega JL, Braunwald E, Murphy SA. , et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51). J Am Coll Cardiol 2013; 61 (18) 1853-1859
  • 26 Ibanez B, James S, Agewall S. , et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (02) 119-177
  • 27 Bosch J, Eikelboom JW, Connolly SJ. , et al. Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial. Can J Cardiol 2017; 33 (08) 1027-1035
  • 28 Connolly SJ, Eikelboom JW, Bosch J. , et al; COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; S0140-6736(17)32458-3
  • 29 Anand SS, Bosch J, Eikelboom JW. , et al; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; Nov 10. pii: S0140-6736(17)32409-1 DOI: 10.1016/S0140-6736(17)32409-1.
  • 30 Anand SS, Caron F, Eikelboom JW. , et al. Major adverse limb events and mortality in patients with peripheral artery disease: The COMPASS trial. J Am Coll Cardiol 2018; 71 (20) 2306-2315
  • 31 Branch KR. , et al. Late-breaking Trial IV: Registries. Paper presented at: Heart Failure 2018 & World Congress on Acute Heart Failure; May 26–29, 2018 ; Vienna
  • 32 Braunwald E. An important step for thrombocardiology. N Engl J Med 2017; 377 (14) 1387-1388